Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation Luís Silva Miguel, Jorge Ferreira

Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting João Morais, Carlos Aguiar, Euan McLeod, Ismini Chatzitheofilou, Isabel Fonseca Santos, Sónia Pereira

Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in PortugalCost-effectiveness of new oral anticoagulants in Portuguese atrial fibrillation patients João Costa, Francesca Fiorentino, Daniel Caldeira, Mónica Inês, Catarina Lopes Pereira, Luís Pinheiro, António Vaz-Carneiro, Margarida Borges, Miguel Gouveia